Impact of Topical Fluocinonide on Oral Lichen Planus Evolution: Randomized Controlled Clinical Trial.

IF 2.9 3区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral diseases Pub Date : 2025-02-01 Epub Date: 2024-10-14 DOI:10.1111/odi.15156

Alessandro Polizzi, Gianluca Martino Tartaglia, Simona Santonocito, Angela Alibrandi, Anna Elisa Verzì, Gaetano Isola

{"title":"Impact of Topical Fluocinonide on Oral Lichen Planus Evolution: Randomized Controlled Clinical Trial.","authors":"Alessandro Polizzi, Gianluca Martino Tartaglia, Simona Santonocito, Angela Alibrandi, Anna Elisa Verzì, Gaetano Isola","doi":"10.1111/odi.15156","DOIUrl":null,"url":null,"abstract":"Objective: To examine the impact of fluocinonide 0.05% gel formulation for the topical treatment of oral lichen planus (OLP).Methods: Through an RCT design, 47 patients with OLP were randomly allocated for topical OLP treatment with fluocinonide 0.05% (n = 23) or placebo (n = 24). Patients were examined for OLP symptoms, signs, disease severity, and extension score changes over 6-month follow-up.Results: After 6 months, in comparison with placebo, patients treated with fluocinonide experienced a significant reduction of OLP symptoms (p = 0.024), signs (p = 0.014), and OLP extension score (p = 0.028). The two-way ANOVA estimation models revealed that treatment with fluocinonide determined, at 6 months, a positive significant effect on the reduced OLP signs (p = 0.017), OLP symptoms (p = 0.026), and OLP extension score (p = 0.028). The multivariate regression analysis highlighted that anxiety, stress, and depression were significant predictors of every analyzed OLP outcome (p < 0.05 for each parameter) and that patients who had baseline anxiety, depression, and stress gained more benefits from fluocinonide at 6-month follow-up.Conclusions: Topical fluocinonide 0.05% was more efficacious compared to placebo in reducing OLP outcomes at 6-month follow-up. Anxiety, depression, and stress were significant predictors of OLP outcomes and positively impacted the treatment with fluocinonide at 6 months.","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":" ","pages":"510-521"},"PeriodicalIF":2.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.15156","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To examine the impact of fluocinonide 0.05% gel formulation for the topical treatment of oral lichen planus (OLP).

Methods: Through an RCT design, 47 patients with OLP were randomly allocated for topical OLP treatment with fluocinonide 0.05% (n = 23) or placebo (n = 24). Patients were examined for OLP symptoms, signs, disease severity, and extension score changes over 6-month follow-up.

Results: After 6 months, in comparison with placebo, patients treated with fluocinonide experienced a significant reduction of OLP symptoms (p = 0.024), signs (p = 0.014), and OLP extension score (p = 0.028). The two-way ANOVA estimation models revealed that treatment with fluocinonide determined, at 6 months, a positive significant effect on the reduced OLP signs (p = 0.017), OLP symptoms (p = 0.026), and OLP extension score (p = 0.028). The multivariate regression analysis highlighted that anxiety, stress, and depression were significant predictors of every analyzed OLP outcome (p < 0.05 for each parameter) and that patients who had baseline anxiety, depression, and stress gained more benefits from fluocinonide at 6-month follow-up.

Conclusions: Topical fluocinonide 0.05% was more efficacious compared to placebo in reducing OLP outcomes at 6-month follow-up. Anxiety, depression, and stress were significant predictors of OLP outcomes and positively impacted the treatment with fluocinonide at 6 months.

查看原文本刊更多论文

外用氟西萘胺对口腔扁平苔藓演变的影响：随机对照临床试验。

目的研究氟西诺奈0.05%凝胶配方对局部治疗口腔扁平苔藓（OLP）的影响：通过RCT设计，47名OLP患者被随机分配接受0.05%氟西诺内酯（23人）或安慰剂（24人）的OLP局部治疗。随访6个月，检查患者的OLP症状、体征、疾病严重程度和扩展评分变化：结果：6个月后，与安慰剂相比，接受氟西诺尼治疗的患者的OLP症状（p = 0.024）、体征（p = 0.014）和OLP扩展评分（p = 0.028）均显著减少。双向方差分析估计模型显示，氟西诺尼治疗 6 个月后，对减少 OLP 体征（p = 0.017）、OLP 症状（p = 0.026）和 OLP 扩展评分（p = 0.028）有积极的显著影响。多变量回归分析显示，焦虑、压力和抑郁对每项分析的 OLP 结果都有显著的预测作用（p 结论：焦虑、压力和抑郁对每项分析的 OLP 结果都有显著的预测作用：与安慰剂相比，0.05%局部氟西诺肽能更有效地减少6个月随访时的OLP结果。焦虑、抑郁和压力是OLP结果的重要预测因素，并对6个月的氟西农内酯治疗产生积极影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral diseases 医学-牙科与口腔外科

CiteScore

7.60

自引率

5.30%

发文量

325

审稿时长

4-8 weeks

期刊介绍： Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.